Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (415)	8/23/1998 3:57:00 AM
From: John Zwiener	Read Replies (1) \| Respond to of 1025

Sam, POC is a fairly well understood concept and is relatively well defined. BMG/Roche has license to central labs, blood banks, and reference labs. POC is outside of the above area, and the instruments would be run by non-lab personal. It is clearly understood what POC means. One area that could be disputed would be sub-labs in very large hospitals, but these are rare, are run by certified lab people, and are part of the structure of the main lab, so these could be considered a part of the central lab if all the various different kinds of tests were run there also, but this would be miniscule. Igen would sell reagents for POC, and doesn't for central lab (BMG/Roche). If Igen did sell reagents to BMG/Roche, there would be no conflict or lawsuit because Igen would get it's money upfront instead of through royalties. I have to disagree with you about this lawsuit hurting Igen. Roche seems to have no trouble placing the electsys. If Roche doesn't want to settle, then they don't get the POC, and someone else does. Wohstadler has hinted that he is holding some kind of agreement, maybe to see if Roche wants to come around. Also, the price of a buyout will continue to go up dramatically because the total business will be bigger and there will more certainy about how big it could get. If we don't see an agreement with Roche next week, then perhaps we would see a POC agreement in the near future. ( I am just theorizing, so I hope there will be no rumors started by this). You mention that a POC prototype is out, and no agreement is out so that can't be all that good, but in fact, it is the ECLM which is being used in the highthruput system and low thruput research instruments currently about to be delivered,,the alpha units that Pfizer, Amgen, Agouron,etc have asked for. The ECLM would also be used in a POC instrument. This ECLM will save major develop costs for any potential POC partner.